We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.      
Continue     Find out more

smiling woman

Questions About Product Support?

Contact OnePath and get connected with a Case Manager.

Call: 1-866-888-0660

Visit OnePath.com to learn more.

Cookies Information

What are cookies?

Cookies are small text files that a website may place on your computer or mobile device when you visit a site or page. Cookies are useful because they allow the website to recognise your device the next time you visit.

How do Shire websites use cookies?

The cookies we use perform three different functions:

1. Strictly necessary cookies

We refer to some cookies as “strictly necessary” cookies because they are essential to enable our visitors to use certain features on our websites. For example, if you enter a username or password to access a secure section of our website, a cookie may be set to keep you from having to enter these details more than once. These cookies do not record personal information that identifies you and are automatically deleted when you close your browser.

2. Performance cookies

These cookies are used to analyse how visitors use our website and to monitor our website’s performance. For example, we may check which pages get the most visits and the average time spent on our website. We use this information to improve how our website works. These cookies do not record personal information that identifies you: the information that we receive from them is in the form of aggregated statistics. These cookies are stored on your device even when you close your browser but can be deleted as described in the paragraph ‘How can I control or delete cookies?’ below.

3. Functionality cookies

These cookies allow our website to provide a more personal experience and remember any choices you may make. For example, if you visit our website using a mobile device but choose to access our main (non-mobile) site, a cookie may be set to prevent you from being re-directed to our mobile site. These cookies do not record personal information that identifies you. These cookies may be stored on your device even when you close your browser but can be deleted as described in the paragraph ‘How can I control or delete cookies?’ below.

How can I control or delete cookies?

Most browsers are initially set up to automatically accept cookies. You can change the settings on your browser to block cookies or to alert you when cookies are being set on your device. You can also delete cookies stored on your device through your browser. Please refer to your browser instructions or Help screen to learn more about how to adjust or modify your browser settings.

Please note that parts of our websites may not function correctly if you disable the cookies.

Version 7 May 2013

INDICATION

VPRIV® (velaglucerase alfa for injection) is a prescription medication indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.

IMPORTANT SAFETY INFORMATION

  • Hypersensitivity reactions, including serious allergic reactions (anaphylaxis) have occurred. VPRIV (velaglucerase alfa for injection) should be administered under the supervision of a healthcare professional. VPRIV is given every other week by intravenous infusion that typically takes up to 60 minutes. Appropriate medical support should be available when VPRIV is administered. The most serious side effects in patients treated with VPRIV were hypersensitivity reactions.
  • Hypersensitivity reactions were the most commonly observed side effects in patients treated with VPRIV in clinical studies. The most commonly observed symptoms of hypersensitivity reactions were: headache, dizziness, low blood pressure, high blood pressure, nausea, tiredness/weakness, and fever. Hypersensitivity reactions in the clinical trials include any event considered related to and occurring within up to 24 hours of VPRIV infusion, including one case of anaphylaxis. Generally the reactions were mild and, in patients not previously treated, occurred mostly during the first 6 months of treatment and tended to occur less frequently with time.
  • If anaphylactic or other acute reactions occur, immediately discontinue the infusion of VPRIV and initiate the appropriate medical treatment. A hypersensitivity reaction should be treated based on the severity of the reaction. Your healthcare provider may manage a reaction by slowing the infusion rate or treating with medicine such as antihistamines, fever-reducing agents and/or corticosteroids or possibly stopping the medication and then restarting with a longer infusion time. For patients who have had symptoms of hypersensitivity reaction to enzyme replacement therapy, the doctor may consider treating the patient with antihistamines and/or corticosteroids before an infusion to help prevent such a reaction from happening.
  • The most commonly reported side effects during clinical studies (in ≥10% of patients) were hypersensitivity reactions, headache, dizziness, abdominal pain, nausea, back pain, joint pain, increased time it takes for blood to clot, tiredness/weakness, and fever. In clinical studies, the overall frequency of side effects was generally higher in the patients not previously treated with ERT than in the patients who switched from imiglucerase to VPRIV.
  • VPRIV is classified as pregnancy category B which means that animal reproduction studies did not show a risk to the unborn and there are no adequate and well-controlled studies in pregnant women. Your doctor may prescribe VPRIV to you if you are pregnant, only if it is clearly necessary.
  • The safety and efficacy profiles were similar in pediatric (ages 4 to 17) and adult patients. The safety of VPRIV has not been established in patients under 4 years of age. Side effects more commonly seen in pediatric patients compared to adult patients include (>10% difference): rash, increased time it takes for blood to clot, and fever.
  • The side effect profile in elderly patients was generally similar to that seen in pediatric and other adult patients. In general, dose selection for an elderly patient should be approached cautiously, considering other existing medical conditions.
  • As with all therapeutic proteins, there is a potential for developing antibodies to VPRIV. In clinical studies, 1 of 54 patients who had not previously been treated with ERT, who were then treated with VPRIV, developed antibodies. It is unknown if having antibodies to VPRIV is associated with a higher risk of infusion reactions. Patients with an immune response to other enzyme replacement therapies who are switching to VPRIV should continue to be monitored for antibodies to VPRIV.
  • Please see full prescribing information.
  • You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.